The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
K S Murphy - One of the best experts on this subject based on the ideXlab platform.
-
oxidation Induced Failure of eb pvd thermal barrier coatings
Surface & Coatings Technology, 2001Co-Authors: V K Tolpygo, David R Clarke, K S MurphyAbstract:Abstract Oxidation-Induced Failure of EB-PVD thermal barrier coatings (TBC) deposited on a single-crystal superalloy with a platinum aluminide bond coat has been studied in order to determine the specific mechanisms leading to TBC spallation. Cyclic oxidation tests performed at 1150°C show that Failure of the TBC occurs when the alumina scale, growing at the bond coat–TBC interface, attains its critical thickness. Therefore, the oxidation rate of the bond coat is considered the major factor affecting TBC durability. The growth rate, morphology and residual stress in the alumina scale depend on the method of the bond coat surface treatment prior to TBC deposition. While the TBC Failure is ultimately driven by the elastic strain energy stored in the scale on cooling, the magnitude of the compressive stress in the scale has no apparent effect on the TBC lifetime. Except for the sample edges, no significant damage in the scale under the TBC has been detected by luminescence spectroscopy prior to Failure.
-
oxidation Induced Failure of eb pvd thermal barrier coatings
Surface & Coatings Technology, 2001Co-Authors: V K Tolpygo, David R Clarke, K S MurphyAbstract:Abstract Oxidation-Induced Failure of EB-PVD thermal barrier coatings (TBC) deposited on a single-crystal superalloy with a platinum aluminide bond coat has been studied in order to determine the specific mechanisms leading to TBC spallation. Cyclic oxidation tests performed at 1150°C show that Failure of the TBC occurs when the alumina scale, growing at the bond coat–TBC interface, attains its critical thickness. Therefore, the oxidation rate of the bond coat is considered the major factor affecting TBC durability. The growth rate, morphology and residual stress in the alumina scale depend on the method of the bond coat surface treatment prior to TBC deposition. While the TBC Failure is ultimately driven by the elastic strain energy stored in the scale on cooling, the magnitude of the compressive stress in the scale has no apparent effect on the TBC lifetime. Except for the sample edges, no significant damage in the scale under the TBC has been detected by luminescence spectroscopy prior to Failure.
V K Tolpygo - One of the best experts on this subject based on the ideXlab platform.
-
oxidation Induced Failure of eb pvd thermal barrier coatings
Surface & Coatings Technology, 2001Co-Authors: V K Tolpygo, David R Clarke, K S MurphyAbstract:Abstract Oxidation-Induced Failure of EB-PVD thermal barrier coatings (TBC) deposited on a single-crystal superalloy with a platinum aluminide bond coat has been studied in order to determine the specific mechanisms leading to TBC spallation. Cyclic oxidation tests performed at 1150°C show that Failure of the TBC occurs when the alumina scale, growing at the bond coat–TBC interface, attains its critical thickness. Therefore, the oxidation rate of the bond coat is considered the major factor affecting TBC durability. The growth rate, morphology and residual stress in the alumina scale depend on the method of the bond coat surface treatment prior to TBC deposition. While the TBC Failure is ultimately driven by the elastic strain energy stored in the scale on cooling, the magnitude of the compressive stress in the scale has no apparent effect on the TBC lifetime. Except for the sample edges, no significant damage in the scale under the TBC has been detected by luminescence spectroscopy prior to Failure.
-
oxidation Induced Failure of eb pvd thermal barrier coatings
Surface & Coatings Technology, 2001Co-Authors: V K Tolpygo, David R Clarke, K S MurphyAbstract:Abstract Oxidation-Induced Failure of EB-PVD thermal barrier coatings (TBC) deposited on a single-crystal superalloy with a platinum aluminide bond coat has been studied in order to determine the specific mechanisms leading to TBC spallation. Cyclic oxidation tests performed at 1150°C show that Failure of the TBC occurs when the alumina scale, growing at the bond coat–TBC interface, attains its critical thickness. Therefore, the oxidation rate of the bond coat is considered the major factor affecting TBC durability. The growth rate, morphology and residual stress in the alumina scale depend on the method of the bond coat surface treatment prior to TBC deposition. While the TBC Failure is ultimately driven by the elastic strain energy stored in the scale on cooling, the magnitude of the compressive stress in the scale has no apparent effect on the TBC lifetime. Except for the sample edges, no significant damage in the scale under the TBC has been detected by luminescence spectroscopy prior to Failure.
Bart Loeys - One of the best experts on this subject based on the ideXlab platform.
-
angiotensin ii type 1 receptor blockade attenuates tgf β Induced Failure of muscle regeneration in multiple myopathic states
Nature Medicine, 2007Co-Authors: Ronald D Cohn, Christel Van Erp, Jennifer Habashi, Arshia Soleimani, Erin C Klein, Matthew T Lisi, Matthew Gamradt, Colette Ap M Rhys, Tammy M Holm, Bart LoeysAbstract:Angiotensin II type 1 receptor blockade attenuates TGF-β–Induced Failure of muscle regeneration in multiple myopathic states
-
angiotensin ii type 1 receptor blockade attenuates tgf β Induced Failure of muscle regeneration in multiple myopathic states
Nature Medicine, 2007Co-Authors: Ronald D Cohn, Christel Van Erp, Jennifer Habashi, Arshia Soleimani, Erin C Klein, Matthew T Lisi, Matthew Gamradt, Colette Ap M Rhys, Tammy M Holm, Bart LoeysAbstract:Skeletal muscle has the ability to achieve rapid repair in response to injury or disease. Many individuals with Marfan syndrome (MFS), caused by a deficiency of extracellular fibrillin-1, exhibit myopathy and often are unable to increase muscle mass despite physical exercise. Evidence suggests that selected manifestations of MFS reflect excessive signaling by transforming growth factor (TGF)-beta (refs. 2,3). TGF-beta is a known inhibitor of terminal differentiation of cultured myoblasts; however, the functional contribution of TGF-beta signaling to disease pathogenesis in various inherited myopathic states in vivo remains unknown. Here we show that increased TGF-beta activity leads to failed muscle regeneration in fibrillin-1-deficient mice. Systemic antagonism of TGF-beta through administration of TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor blocker losartan normalizes muscle architecture, repair and function in vivo. Moreover, we show TGF-beta-Induced Failure of muscle regeneration and a similar therapeutic response in a dystrophin-deficient mouse model of Duchenne muscular dystrophy.
-
Angiotensin II type 1 receptor blockade attenuates TGF-β–Induced Failure of muscle regeneration in multiple myopathic states
Nature medicine, 2007Co-Authors: Ronald D Cohn, Christel Van Erp, Jennifer Habashi, Arshia Soleimani, Erin C Klein, Matthew T Lisi, Matthew Gamradt, Colette Ap M Rhys, Tammy M Holm, Bart LoeysAbstract:Angiotensin II type 1 receptor blockade attenuates TGF-β–Induced Failure of muscle regeneration in multiple myopathic states
David R Clarke - One of the best experts on this subject based on the ideXlab platform.
-
oxidation Induced Failure of eb pvd thermal barrier coatings
Surface & Coatings Technology, 2001Co-Authors: V K Tolpygo, David R Clarke, K S MurphyAbstract:Abstract Oxidation-Induced Failure of EB-PVD thermal barrier coatings (TBC) deposited on a single-crystal superalloy with a platinum aluminide bond coat has been studied in order to determine the specific mechanisms leading to TBC spallation. Cyclic oxidation tests performed at 1150°C show that Failure of the TBC occurs when the alumina scale, growing at the bond coat–TBC interface, attains its critical thickness. Therefore, the oxidation rate of the bond coat is considered the major factor affecting TBC durability. The growth rate, morphology and residual stress in the alumina scale depend on the method of the bond coat surface treatment prior to TBC deposition. While the TBC Failure is ultimately driven by the elastic strain energy stored in the scale on cooling, the magnitude of the compressive stress in the scale has no apparent effect on the TBC lifetime. Except for the sample edges, no significant damage in the scale under the TBC has been detected by luminescence spectroscopy prior to Failure.
-
oxidation Induced Failure of eb pvd thermal barrier coatings
Surface & Coatings Technology, 2001Co-Authors: V K Tolpygo, David R Clarke, K S MurphyAbstract:Abstract Oxidation-Induced Failure of EB-PVD thermal barrier coatings (TBC) deposited on a single-crystal superalloy with a platinum aluminide bond coat has been studied in order to determine the specific mechanisms leading to TBC spallation. Cyclic oxidation tests performed at 1150°C show that Failure of the TBC occurs when the alumina scale, growing at the bond coat–TBC interface, attains its critical thickness. Therefore, the oxidation rate of the bond coat is considered the major factor affecting TBC durability. The growth rate, morphology and residual stress in the alumina scale depend on the method of the bond coat surface treatment prior to TBC deposition. While the TBC Failure is ultimately driven by the elastic strain energy stored in the scale on cooling, the magnitude of the compressive stress in the scale has no apparent effect on the TBC lifetime. Except for the sample edges, no significant damage in the scale under the TBC has been detected by luminescence spectroscopy prior to Failure.
Sookeun Lee - One of the best experts on this subject based on the ideXlab platform.
-
antibody Induced Failure of botulinum toxin type a therapy in a patient with masseteric hypertrophy
Dermatologic Surgery, 2007Co-Authors: Sookeun LeeAbstract:BACKGROUND With the expanding use of botulinum toxin, much concern about the antibody against botulinum toxin is arising. Unlike neurologic indications such as cervical dystonia, antibody-Induced Failure of botulinum toxin therapy has never been reported in the cosmetic field. OBJECTIVE The objective was to describe a case of an antibody-Induced Failure of botulinum toxin type A (BTX-A) therapy (BOTOX, Allergan, Inc.) that occurred in a patient with masseteric hypertrophy. METHODS AND MATERIALS We present a 20-year-old girl who developed antibody-Induced therapy Failure after the fourth injection series. Sixty units of toxin was injected at each series and the intertreatment interval was four to five months. RESULTS Frontalis test revealed no paresis of muscle after a unilateral injection of BTX-A. Circulating antibodies against BTX-A were detected by indirect enzyme-linked immunosorbent assay and mouse protection assay. CONCLUSION This case is unique in that, first, immunoresistance developed in a patient of cosmetic indication where only a small dose of BTX-A was administered and, second, antibodies developed on the so-called new formulation of BOTOX. Our case alerts cosmetic surgeons to the importance of antibody against the botulinum toxin.
-
Antibody-Induced Failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2007Co-Authors: Sookeun LeeAbstract:With the expanding use of botulinum toxin, much concern about the antibody against botulinum toxin is arising. Unlike neurologic indications such as cervical dystonia, antibody-Induced Failure of botulinum toxin therapy has never been reported in the cosmetic field. The objective was to describe a case of an antibody-Induced Failure of botulinum toxin type A (BTX-A) therapy (BOTOX, Allergan, Inc.) that occurred in a patient with masseteric hypertrophy. We present a 20-year-old girl who developed antibody-Induced therapy Failure after the fourth injection series. Sixty units of toxin was injected at each series and the intertreatment interval was four to five months. Frontalis test revealed no paresis of muscle after a unilateral injection of BTX-A. Circulating antibodies against BTX-A were detected by indirect enzyme-linked immunosorbent assay and mouse protection assay. This case is unique in that, first, immunoresistance developed in a patient of cosmetic indication where only a small dose of BTX-A was administered and, second, antibodies developed on the so-called new formulation of BOTOX. Our case alerts cosmetic surgeons to the importance of antibody against the botulinum toxin.